Piper Sandler downgraded Galera Therapeutics to Neutral from Overweight with a price target of 50c, down from $6. The FDA issued a Complete Response Litter for avasopasem for the prevention of severe oral mucositis caused by radiation therapy for head and neck cancer and said an additional clinical trial would be required the analyst tells investors in a research note. The firm downgraded the shares on the news.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRTX: